Chronic Bronchitis

Chronic bronchitis is a chronic inflammatory disease of the bronchi and bronchioles, characterized by a persistent cough for at least two consecutive months within a 12-month period, without evidence of other underlying diseases such as heart failure, neoplasia, or infectious pneumonia. The condition is defined by the presence of excessive mucus production and airway remodeling, leading to airway obstruction and impaired gas exchange. In veterinary medicine, chronic bronchitis is most commonly diagnosed in middle-aged to older dogs, particularly small and toy breeds, and less frequently in cats. The disease is progressive and irreversible, with a focus on managing clinical signs and slowing disease progression. The hallmark is a chronic, non-productive or productive cough that is often exacerbated by exercise, excitement, or tracheal palpation. The diagnosis is based on clinical signs, thoracic radiography, and bronchoscopy with bronchoalveolar lavage (BAL) to rule out other causes of chronic cough.

The exact etiology of chronic bronchitis is often multifactorial and may involve a combination of environmental, infectious, and host factors. Primary causative agents include chronic exposure to inhaled irritants such as cigarette smoke, dust, allergens, and air pollutants. In dogs, chronic bronchitis is frequently associated with chronic airway inflammation, which may be triggered by recurrent respiratory infections, although a specific infectious agent is rarely identified. In cats, chronic bronchitis is often linked to feline asthma, but it can also occur independently. Potential infectious agents include Mycoplasma spp., Bordetella bronchiseptica, and various viral pathogens, but their role in the chronicity of the disease is not fully understood. Genetic predisposition may play a role, as certain breeds are overrepresented. The inflammatory response involves an influx of neutrophils, macrophages, and lymphocytes into the airway walls, leading to mucus gland hyperplasia, goblet cell metaplasia, and smooth muscle hypertrophy. These changes result in airway narrowing and excessive mucus production, perpetuating the cough and further airway damage.

Chronic bronchitis is primarily a disease of middle-aged to older dogs, with a median age of onset around 8-10 years. Small and toy breeds, such as the West Highland White Terrier, Cocker Spaniel, Poodle, and Beagle, are overrepresented. There is no clear sex predilection. In cats, chronic bronchitis is less common than feline asthma but can occur in any breed, with a slight predilection for Siamese and other Oriental breeds. The incidence is higher in environments with poor air quality, such as homes with smokers or high levels of dust. Geographic variations may exist due to climate and air pollution. The disease is chronic and progressive, with a variable course depending on the severity of airway remodeling and the presence of concurrent conditions such as obesity or tracheal collapse.

The pathophysiology of chronic bronchitis involves a complex interplay of inflammatory cells, cytokines, and structural changes in the airways. Chronic exposure to irritants or allergens triggers an inflammatory cascade, with activation of epithelial cells and resident macrophages. These cells release pro-inflammatory cytokines (e.g., TNF-α, IL-8, IL-1β) that recruit neutrophils and other leukocytes into the airway lumen and submucosa. Neutrophils release proteases and reactive oxygen species, causing epithelial damage and mucus gland hyperplasia. Goblet cell metaplasia leads to increased mucus production, while impaired mucociliary clearance results in mucus accumulation and airway obstruction. Chronic inflammation induces structural remodeling, including smooth muscle hypertrophy, subepithelial fibrosis, and basement membrane thickening. These changes lead to irreversible airway narrowing, increased airway resistance, and air trapping. The cough reflex is stimulated by the presence of excessive mucus and airway inflammation. Over time, the disease can lead to bronchiectasis, pulmonary hypertension, and cor pulmonale in severe cases.

Intrinsic risk factors include genetic predisposition, as certain breeds are more susceptible, and age, with older animals being more commonly affected. Obesity is a significant risk factor, as it increases the work of breathing and exacerbates airway obstruction. Concurrent conditions such as tracheal collapse, laryngeal paralysis, or dental disease can predispose to chronic bronchitis. Extrinsic factors include exposure to environmental tobacco smoke, air pollution, dust, and allergens. Poor ventilation in the home, use of aerosolized chemicals, and high humidity can also contribute. Immunosuppression, whether due to stress, concurrent illness, or medication, may increase susceptibility to respiratory infections that can trigger or worsen chronic bronchitis. In cats, chronic bronchitis may be associated with chronic stress or obesity.

The primary clinical sign is a chronic, persistent cough that lasts for at least two months. The cough may be dry or productive, and is often worse in the morning, with exercise, or upon excitement. In dogs, the cough may be triggered by tracheal palpation or pulling on a leash. Cats may exhibit a hacking cough, sometimes mistaken for hairballs. Other signs include exercise intolerance, wheezing, and respiratory distress in severe cases. On physical examination, crackles and wheezes may be auscultated over the lung fields. In advanced stages, cyanosis, syncope, and signs of right-sided heart failure (e.g., jugular distension, ascites) may be present due to cor pulmonale. The disease is progressive, and clinical signs may worsen over time if not managed appropriately.

Differential diagnoses for chronic bronchitis include: 1) Feline asthma (in cats), which is characterized by eosinophilic airway inflammation and reversible bronchoconstriction; 2) Tracheal collapse, which presents with a honking cough and is often seen in small breed dogs; 3) Bronchiectasis, which is a permanent dilation of the bronchi due to chronic inflammation; 4) Pulmonary neoplasia, which may present with a chronic cough and weight loss; 5) Heart failure (left-sided congestive heart failure), which can cause coughing due to pulmonary edema; 6) Infectious pneumonia (bacterial, fungal, or parasitic), which typically presents with fever, lethargy, and abnormal lung sounds; 7) Chronic interstitial lung disease, such as pulmonary fibrosis, which may have similar clinical signs; 8) Foreign body aspiration, which can cause chronic coughing and is often associated with a history of acute onset; 9) Laryngeal paralysis, which can cause coughing and respiratory distress; 10) Ciliary dyskinesia, a congenital condition leading to recurrent respiratory infections.

The diagnostic algorithm for chronic bronchitis begins with a thorough history and physical examination. If a chronic cough is present, thoracic radiographs are obtained to evaluate the lungs and heart. Radiographic findings may include bronchial pattern, peribronchial cuffing, and in advanced cases, bronchiectasis or pulmonary overinflation. If radiographs are inconclusive or if the patient is not responding to symptomatic treatment, bronchoscopy is indicated. Bronchoscopy allows direct visualization of the airways, revealing erythema, edema, excessive mucus, and airway collapse. During bronchoscopy, bronchoalveolar lavage (BAL) is performed to collect fluid for cytology and culture. Cytology typically shows neutrophilic inflammation in dogs and a mixed or eosinophilic pattern in cats. Bacterial culture and sensitivity are performed to rule out secondary infection. Additional tests may include heartworm antigen testing, fecal examination for lungworms, and blood work to rule out systemic disease. In cases where heart disease is suspected, echocardiography is recommended. A definitive diagnosis is based on the presence of chronic cough, radiographic evidence of bronchial disease, and bronchoscopic findings, with exclusion of other causes.

Complete blood count (CBC) is often unremarkable, but may show mild neutrophilia or eosinophilia in some cases. Serum biochemistry is typically normal, but may reveal elevated liver enzymes if cor pulmonale is present. Arterial blood gas analysis may show hypoxemia and hypercapnia in severe cases. Bronchoalveolar lavage (BAL) fluid analysis is crucial: in dogs, it typically shows a high neutrophil count (>50% of nucleated cells), while in cats, it may show eosinophilia (if asthma) or neutrophilia. BAL fluid should be submitted for bacterial culture and sensitivity. Fecal examination for lungworm larvae (e.g., Angiostrongylus vasorum, Oslerus osleri) is recommended, especially in endemic areas. Heartworm antigen testing is advised in dogs. In cats, serology for feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) may be considered. Biomarkers such as C-reactive protein (CRP) may be elevated in inflammatory conditions, but are not specific.

Thoracic radiography is the primary imaging modality. Findings include a prominent bronchial pattern, often described as 'doughnuts' and 'tramlines', due to thickened bronchial walls. Peribronchial cuffing may be present. In advanced cases, bronchiectasis may be seen as dilated, thick-walled bronchi that do not taper normally. Pulmonary overinflation may be evident as flattening of the diaphragm and increased lucency of the lung fields. In cats, a bronchial pattern is also common, but may be accompanied by a patchy alveolar pattern if there is concurrent pneumonia. Computed tomography (CT) is more sensitive than radiography for detecting bronchiectasis and subtle airway changes, and may be recommended in complex cases. Bronchoscopy is an essential imaging tool for direct visualization of the airways, allowing assessment of erythema, edema, mucus accumulation, and airway collapse. Fluoroscopy can be used to evaluate dynamic airway collapse during breathing.

Bronchoalveolar lavage (BAL) cytology is the primary diagnostic sample. In chronic bronchitis, the BAL fluid typically shows a marked increase in neutrophils (often >50% of nucleated cells) in dogs, while cats may have a mixed population with eosinophils, neutrophils, and macrophages. The presence of mucus, goblet cells, and Curschmann's spirals may be noted. Histopathology of bronchial biopsies, obtained via bronchoscopy, reveals chronic inflammation with infiltration of lymphocytes, plasma cells, and neutrophils in the lamina propria. There is hyperplasia of mucus glands and goblet cells, smooth muscle hypertrophy, and fibrosis of the bronchial wall. In severe cases, there may be destruction of the bronchial cartilage and bronchiectasis. Special stains, such as Masson's trichrome, can highlight fibrosis. These findings are consistent with chronic bronchitis and help differentiate it from other conditions like asthma (eosinophilic infiltration) or neoplasia.

The treatment of chronic bronchitis is multimodal and aims to reduce inflammation, control clinical signs, and slow disease progression. The first step is to identify and eliminate any environmental irritants, such as cigarette smoke, dust, and allergens. Weight management is crucial in obese patients. Medical therapy includes: 1) Corticosteroids: Oral prednisone or prednisolone is the mainstay of anti-inflammatory therapy. In dogs, prednisone is typically started at 0.5-1 mg/kg PO q12h for 7-14 days, then tapered to the lowest effective dose (e.g., 0.5 mg/kg q48h). In cats, prednisolone is preferred (0.5-1 mg/kg PO q12h, then tapered). Inhaled corticosteroids (e.g., fluticasone propionate) may be used via a spacer and mask, especially in cats, to minimize systemic side effects. 2) Bronchodilators: Theophylline (extended-release) at 10-20 mg/kg PO q12h in dogs, and 15-20 mg/kg PO q24h in cats, can help improve airflow. Alternatively, terbutaline (0.01 mg/kg SC or 0.625-1.25 mg per cat PO q8-12h) may be used. 3) Antitussives: If the cough is severe and non-productive, butorphanol (0.05-0.1 mg/kg PO q6-12h) or hydrocodone (0.22 mg/kg PO q6-8h) may be used, but caution is advised as coughing is a protective mechanism. 4) Antibiotics: If secondary bacterial infection is confirmed by culture, appropriate antibiotics should be administered for 2-3 weeks. 5) Mucolytics: N-acetylcysteine (50-100 mg/kg PO q8h) may help reduce mucus viscosity, but evidence is limited. 6) Supportive care: Oxygen therapy in hypoxemic patients, and fluid therapy to maintain hydration. In severe cases with cor pulmonale, treatment for right-sided heart failure (e.g., furosemide, pimobendan) may be necessary.

The prognosis for chronic bronchitis is generally fair to good with appropriate management, but the disease is progressive and irreversible. Many dogs and cats can maintain a good quality of life for years with medical therapy and environmental modifications. The response to corticosteroids is often favorable, with a reduction in cough frequency and severity. However, some patients may require long-term, high-dose corticosteroids, leading to potential side effects. Negative prognostic indicators include the presence of bronchiectasis, cor pulmonale, and poor response to therapy. The median survival time in dogs with chronic bronchitis has been reported to be around 2-3 years, but this varies widely. In cats, the prognosis is similar, with many cats living for several years with appropriate treatment. Regular monitoring and dose adjustments are essential to optimize outcomes.

Follow-up is essential to monitor response to therapy and adjust medications. Initially, patients should be re-evaluated 2-4 weeks after starting treatment to assess clinical response and check for adverse effects. Thereafter, re-checks every 3-6 months are recommended. At each visit, a thorough physical examination, body weight measurement, and thoracic auscultation should be performed. Owners should be asked about cough frequency and severity. Serial thoracic radiographs may be taken every 6-12 months to monitor for progression of bronchial changes or development of bronchiectasis. If the patient is on long-term corticosteroids, blood pressure, urine cortisol-to-creatinine ratio, and serum biochemistry should be monitored periodically to detect iatrogenic hyperadrenocorticism. Inhaled corticosteroid use may reduce systemic side effects, but proper technique must be ensured. If clinical signs worsen, additional diagnostics such as bronchoscopy and BAL may be repeated to rule out secondary infection or other complications.

Pearls: 1) Always rule out heart disease in older dogs with a cough before assuming chronic bronchitis; thoracic radiographs and echocardiography are key. 2) In cats, differentiate chronic bronchitis from feline asthma; BAL cytology is essential (eosinophils suggest asthma). 3) Environmental control is the most important non-pharmacological intervention; ask about smoking, fireplace use, and cleaning products. 4) Inhaled corticosteroids are underutilized in dogs; they can reduce systemic side effects. 5) Use a tapering course of corticosteroids to find the lowest effective dose. Pitfalls: 1) Overuse of antitussives can suppress the cough reflex and lead to mucus retention and secondary pneumonia. 2) Antibiotics are often prescribed unnecessarily; only use if there is confirmed bacterial infection. 3) Failure to address obesity can undermine treatment efficacy. 4) In cats, using prednisone instead of prednisolone may result in poor absorption; prednisolone is preferred. 5) Not recognizing the development of cor pulmonale can lead to sudden death; monitor for signs of right-sided heart failure.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Prednisone (dogs): 0.5-1 mg/kg PO q12h for 7-14 days, then taper to 0.5-1 mg/kg PO q48h or the lowest effective dose. For cats: Prednisolone 1-2 mg/kg PO q12h, then taper to 0.5-1 mg/kg q48h. 2) Fluticasone propionate (inhaled): 110-220 mcg per dog or cat, administered via a spacer and mask, q12h. 3) Theophylline (extended-release): Dogs: 10-20 mg/kg PO q12h; Cats: 15-20 mg/kg PO q24h. Monitor serum levels if possible (therapeutic range 10-20 mcg/mL). 4) Terbutaline: Dogs: 0.01 mg/kg SC or 0.625-1.25 mg per cat PO q8-12h. 5) Butorphanol: 0.05-0.1 mg/kg PO q6-12h for cough suppression. 6) Hydrocodone: 0.22 mg/kg PO q6-8h. 7) N-acetylcysteine: 50-100 mg/kg PO q8h. 8) Antibiotics: Based on culture and sensitivity; common choices include doxycycline (5-10 mg/kg PO q12h) or amoxicillin-clavulanate (12.5-25 mg/kg PO q12h) for 2-3 weeks. 9) For cor pulmonale: Furosemide (1-2 mg/kg PO q8-12h) and pimobendan (0.25-0.3 mg/kg PO q12h) may be used. Always adjust dosages for renal or hepatic impairment and monitor for drug interactions.

Key studies and consensus guidelines: 1) The ACVIM consensus statement on the diagnosis and management of chronic bronchitis in dogs (2015) emphasizes the importance of bronchoscopy and BAL for diagnosis. 2) A study by Johnson et al. (2005) reported that inhaled fluticasone was as effective as oral prednisone in controlling clinical signs in dogs with chronic bronchitis, with fewer systemic side effects. 3) A retrospective study by Adamama-Moraitou et al. (2004) found that dogs with chronic bronchitis had a median survival of 2.5 years, with worse prognosis in those with bronchiectasis. 4) In cats, a study by Foster et al. (2004) compared prednisolone and inhaled fluticasone, showing similar efficacy but better safety profile with inhaled therapy. 5) The ISCAID guidelines on antimicrobial use in respiratory tract infections (2017) recommend against routine antibiotic use in chronic bronchitis unless there is confirmed bacterial infection. 6) A meta-analysis by Cocayne et al. (2015) concluded that environmental tobacco smoke is a significant risk factor for chronic bronchitis in dogs. These studies support the current approach of anti-inflammatory therapy, environmental control, and judicious use of antibiotics.